 Home > Active Ingredient News > Antitumor Therapy > JAMA Oncol: Capecitabine maintenance therapy significantly improves survival in patients with metastatic nasopharyngeal carcinoma

JAMA Oncol: Capecitabine maintenance therapy significantly improves survival in patients with metastatic nasopharyngeal carcinoma

 Last Update: 2022-03-05
 Source: Internet
 Author: User

Tags

primary fibromyalgia syndrome

free rape

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Capecitabine maintenance therapy improves survival outcomes in patients with various types of cancer, but data on the efficacy and safety of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma (NPC) are limited
.

This study aimed to evaluate the efficacy and safety of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma
.

This is a randomized phase 3 clinical trial conducted at Sun Yat-sen University Cancer Center in China.
Between May 16, 2015 and January 9, 2020, a total of 104 newly diagnosed patients with metastatic nasopharyngeal carcinoma were recruited.
The patient achieved disease control after induction chemotherapy with paclitaxel, cisplatin, and capecitabine (4-6 cycles)
.

Subjects were randomized 1:1 into two groups to receive capecitabine maintenance therapy (1000 mg/m2, 2/day, orally, two weeks on and one week off) + best supportive care (BSC) or only Accept BSC

PFS and duration of remission in the two groups of patients

There were 52 patients each in the capecitabine group and the BSC group
.

After a median follow-up of 33.

Adverse events in the two groups

During maintenance therapy, the most common grade 3/4 adverse events were anemia (12.
0%), hand-foot syndrome (10.
0%), nausea and vomiting (6.
0%), fatigue (4.
0%), and mucositis (4.
0%)
.

There were no treatment-related deaths

In conclusion, for patients with metastatic nasopharyngeal carcinoma who achieved disease control after induction chemotherapy with capecitabine-containing regimen, capecitabine maintenance therapy can significantly prolong event-free survival with controllable side effects

For patients with metastatic nasopharyngeal carcinoma who achieved disease control after induction chemotherapy with capecitabine-containing regimen, capecitabine maintenance therapy can significantly prolong event-free survival, and the toxic and side effects are controllable .

Original source:

Liu Guo-Ying,Li Wang-Zhong,Wang De-Shen et al.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.